Quality assured
Confidentiality assured
Custom research services
Preliminary research of Fairfield Market Research indicates a promising growth outlook for global endometriosis treatment market during the course of next few years.
Delayed Diagnosis Directly Influences Growth of Endometriosis Treatment Market
Increasing disease awareness, increasing disease burden, and a strong product pipeline are some key factors propelling expansion of the endometriosis treatment market. Additionally, there was fierce competition in the market from off-label, and generic medications, which would limit its expansion. Around 190 million women of reproductive age, or 10% of all women worldwide, have endometriosis, according to a March 2021 World Health Organization report. Healthcare professionals also report a delay in diagnosis due to the various and widespread endometriosis symptoms. The symptoms worsen due to the delayed diagnosis, increasing the need for therapy. Additionally, people affected by the illness have little knowledge of it. These and other factors drive the market by driving up treatment demand.
Every year in March, endometriosis awareness campaigns are held in many nations to spread knowledge about the condition. For instance, on March 12, Austria will conduct a free, all-day online congress featuring information on endometriosis. The Endometriosis and Reproductive Health Foundation in Bulgaria hosted a virtual conference titled Myths and truths about the condition on March 19 and 20, 2022. On these forums, subject matter experts dispel common misconceptions about the illness. Similar initiatives have been launched in Canada, Bangladesh, Finland, France, Hungary, India, and many other nations worldwide to promote open dialogue about endometriosis. Such initiatives are therefore driving the market for endometriosis treatment. Government and major endometriosis treatment market participants aggressively invest in R&D and raise finances nationally and worldwide, supporting the market expansion. For instance, the U.S. federal government announced in March 2022 that NICHD would receive US$92 Mn in funding for endometriosis research.
Endometriosis Treatment Market: COVID-19 Impact
The COVID-19 pandemic significantly influenced patients who suffer from chronic illnesses like endometriosis. Demand for goods across all categories decreased due to the stringent lockdowns and government measures designed to stop the spread of COVID-19. Women with endometriosis are more susceptible to developing post-traumatic stress disorder during the COVID-19 epidemic, especially if they are older or have greater anxiety levels. According to research published in October 2021 in the National Library of Medicine titled "Effects of the SARS-CoV-2 pandemic on women affected by endometriosis," 68.8% of these women were very concerned about not being able to access gynecologic care during this time. As a result, COVID-19 significantly impacted the market.
Growing Endometriosis Prevalence, and Increasing Healthcare Spending Drive Endometriosis Treatment Market
Endometriosis is becoming more common, and as a result, people are more knowledgeable about its treatment. The increased prevalence of the condition has also increased the focus on research and development. Additionally, government organizations are spending money on healthcare infrastructure to give patients greater treatment options. As a result, the endometriosis treatment market will grow as new medications and diagnostic tools for treating endometriosis are needed. The World Health Organization estimates that 10% (190 million) of women and girls of reproductive age will have endometriosis by 2021. In addition, increasing endometriosis prevalence, more knowledge of the condition, and increased demand for early detection are key drivers propelling market expansion.
Increased Focus on R&D Facilitates Expansion of Endometriosis Treatment Market
The rise in the number of people with this illness being diagnosed globally, the proportion of women in the reproductive age group, and the expansion of research-based efforts to provide more potent medications for treatment are all key drivers of the global endometriosis treatment market's revenue growth. The development of the worldwide market is also being aided by government programs aimed at improving women's health and activities by nonprofit and for-profit groups to raise awareness of the condition and the value of an early diagnosis through social media campaigns. High demand for hormone therapeutics as a form of treatment, increasing funding for enhancing healthcare infrastructure and facilities, the availability of different patient assistance programs to lessen the financial burden on patients, and manufacturers focusing more on creating high-efficiency therapeutics to meet unmet medical needs are all factors that are boosting market revenue growth. Additionally, the rising prevalence of various gynecological diseases, rising demand for non-invasive diagnosis methods, and ongoing research into developing new, effective medications to counteract the negative effects of current medications are all predicted to lead to lucrative revenue growth opportunities for both established industry leaders and newcomers in the market.
Lack of Non-invasive Diagnostic Tests Stands as a Significant Barrier to Endometriosis Treatment Market Growth
Many negative factors, including a lack of non-invasive diagnostic tests, a shortage of qualified healthcare workers, and a lack of cutting-edge treatment facilities in several developing and undeveloped nations, significantly impede the growth of the global endometriosis treatment market. Other factors, such as the high cost of sophisticated therapeutic medications and the high funding requirements for developing novel drugs, may somewhat restrain market revenue growth during the projected period. Additionally, the potential for negative effects from Gonadotropin-Releasing Hormone (GnRH) drugs, such as hot flashes, headaches, joint and muscle stiffness, and vaginal dryness, to manifest in the future could restrain the market expansion.
NSAIDs Category Dominates Endometriosis Treatment Market As Number of Patients with Epilepsy Soars
The NSAIDs category held the largest endometriosis treatment market share, and it is anticipated that it will continue to rule the market during the forecast period because they provide rapid pain relief, over-the-counter and prescription medications are often used as the first line of treatment because they are affordable and readily accessible. Paracetamol, ibuprofen, and naproxen are nonsteroidal anti-inflammatory medications that lessen mild to moderate pain by preventing the synthesis of prostaglandins. On the other hand, the GnRH analogs category is anticipated to grow significantly over the forecast period. They are available as a tablet, injection, shot, or nasal spray. Orilissa (elagolix), manufactured by AbbVie Inc., was the first drug given FDA approval to alleviate disease-related pain. Zoladex, Lupron, Orilissa, and Synarel are examples of GnRH agonists and antagonists suggested as alternatives for patients resistant to the first therapy. The main benefit of the therapy is that once it is over, the woman resumes having regular menstrual cycles, and her potential to become pregnant is unaffected.
Pain Management Category Leads Endometriosis Treatment Market Owing to Fewer Side Effects of Medication
The pain management category dominated the endometriosis treatment market in 2021. Patients with endometriosis endure unpleasant symptoms like dysmenorrhea and dyspareunia, persistent pelvic discomfort, infertility, and emotional distress. As a result, the negative effects that drugs that suppress painful disease symptoms have on mental health and quality of life progressively diminish. This medication drives the market since it has fewer side effects, good tolerance, affordable costs, and a high safety profile. Besides, the hormonal therapy category is anticipated to grow significantly over the forecast period. The expansion of the hormone therapy market is anticipated to be fueled by popular therapeutic goods like Yselty (linzagolix) from ObsEva and Myovant/Relugolix Pfizer's combination pill. In addition, strategic cooperation between important players is anticipated to fuel market expansion.
Revenue Generation Remains Concentrated in North America’s Endometriosis Treatment Market, Government Financing Crucial
Over the forecast period, the North America endometriosis treatment market will account for the largest revenue share. It can be ascribed to factors including rising endometriosis prevalence, rising disease awareness in this area, and the accessibility of high-tech items. For instance, 1 in 10 women between the ages of 15 and 44 in the U.S. will have the disease in 2021, affecting around 6.5 million women. The market for endometriosis treatments is expanding partly due to the approval of innovative products and their subsequent launches. For instance, in August 2022, the FDA authorized Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) from Myovant Sciences and Pfizer for use as a pain management drug in premenopausal women with the condition.
The Asia Pacific endometriosis treatment market is anticipated to experience stable revenue growth throughout the forecast period due to major market players developing their operations there. The increase in disease cases and the strategic actions made by market players for regional expansion in such places are credited with the region's growth. Additionally, it is projected that rising research and development, as well as rising investments to create and sell such new delivery methods, will accelerate the market expansion in the region. To reach the underserved segments of society, governments in China and India are dramatically expanding their healthcare budgets.
Global Endometriosis Treatment Market: Competitive Landscape
In February 2022, Theramex and ObsEva SA declared their strategic licensing 'arrangement' to support Linzagolix's commercialization and market expansion on a global scale. Similarly, in January 2022, ObsEva SA reported favorable topline findings from the Phase 3 EDELWEISS 3 trial of the oral GnRH antagonist linzagolix in patients with moderate-to-severe endometriosis-related pain (EAP).
A few players in the endometriosis treatment market are Bayer AG, Pfizer, Inc., AbbVie, Inc, AstraZeneca, ObsEva SA, Teva Pharmaceutical Industries, Zydus Healthcare Limited, Eli Lilly and Company and Astellas Pharma Inc.
Global Endometriosis Treatment Market is Segmented as Below:
By Drugs
By Treatment Type
By Distribution Channel
By Region
Key Elements Included In The Study: Global Endometriosis Treatment Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Disclaimer:
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.
View Methodology
Quality assured
Confidentiality assured
Custom research services
